Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Y-90 clivatuzumab tetraxetan - Immunomedics

Drug Profile

Y-90 clivatuzumab tetraxetan - Immunomedics

Alternative Names: 90Y-clivatuzumab tetraxetan; 90Y-hPAM4; 90y-Hpama4; Clivatucyn; Clivatuzumab; Clivatuzumab tetraxetan; Clivatuzumab tetraxetan Y-90; Clivatuzumab Y-90; hPAM4-Cide; hPAM4-DOTA; Humanised monoclonal antibody PAM4 Y-90; IMMU-107; Monoclonal antibody PAM4-Y-90; Pan-Cide; Y-90 clivatuzumab; Yttrium-(90Y) clivatuzumab tetraxetan; Yttrium-90 clivatuzumab tetraxetan; Yttrium-90 labelled monoclonal antibody PAM4

Latest Information Update: 18 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pancreatic cancer

Most Recent Events

  • 18 Jan 2018 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, First-line therapy) in USA and Germany (IV), because not listed on Immunomedics pipeline, January 2018
  • 18 Jan 2018 Discontinued - Phase-III for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Poland, France, Belgium, Israel, Canada, Spain, Austria and USA (IV), further to negative results from the PANCRIT® 1 trial
  • 14 Mar 2016 Immunomedics terminates the PANCRIT-1 phase III trial in Pancreatic cancer in Austria, Belgium, Canada, France, Israel, Poland, Spain and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top